Cavernous Malformation Hemorrhagic Presentation at Diagnosis Associated with Low 25-Hydroxy-Vitamin D Level

被引:13
作者
Flemming, Kelly D. [1 ]
Kumar, Shivram [1 ]
Brown, Robert D., Jr. [1 ]
Singh, Ravinder J. [3 ]
Whitehead, Kevin [4 ]
McCreath, Lauren [4 ]
Lanzino, Giuseppe [2 ]
机构
[1] Mayo Clin, Dept Neurol, W8B Mayo Bldg,200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[4] Univ Utah, Dept Cardiovasc Med, Salt Lake City, UT USA
关键词
Cavernous malformation; Hemorrhage; Cavernoma; Cavernous; Angioma; Vitamin D; 25-Hydroxy-vitamin D; VITAMIN-D;
D O I
10.1159/000507789
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Cavernous malformations (CM) are angiographically occult vascular malformations that may be incidental or present with intracerebral or spinal hemorrhage, seizures, or nonhemorrhagic focal neurologic deficit (FND). Recently in vitro data have suggested vitamin D may play a role in stabilizing CCM2 endothelial cells. Little is known about the effect of vitamin D in human CM disease. Methods: Beginning in 2015, consecutive patients at our institution with radiologically confirmed CM were recruited to participate in a prospective clinical registry as well as 25-hydroxy-vitamin D study. A structured interview, survey, and examination were performed at baseline. Medical records and magnetic resonance imaging studies were reviewed and data collected included comorbid conditions, medication use, and location of CM. Standard definition of clinical hemorrhage, FND, and seizures was used. Univariate and multivariate logistic regression models were used, and OR, 95% CIs, and likelihood-ratio p values were calculated to determine the influence of the 25-hydroxy-vitamin D level on clinical presentation with hemorrhage. Results: Of 213 patients enrolled in the clinical registry between January 2015 and October 2018, 70 participated in the vitamin D study (median age: 38.3 years; 51.4% female). Of the 70 participants, 30 (42.9%) presented with hemorrhage. 25-Hydroxy-vitamin D levels were performed within 1 year of symptoms in 64.1% of patients. Patients presenting with hemorrhage had a lower 25-hydroxy-vitamin D level compared to those presenting with seizure without hemorrhage, FND, or as an incidental finding (median 25.5 ng/mL; range 11-59 hemorrhage vs. median 31.0; range 14-60, no hemorrhage; p = 0.04). After adjusting for age, month of blood draw, and body mass index, 25-hydroxy-vitamin D remained a significant predictor of hemorrhagic presentation. Brainstem location also predicted hemorrhage at presentation. Conclusion: Low 25-hydroxy-vitamin D level was more common in patients with CM presenting with hemorrhage. This study supports the potential role of modifiable factor in the initial clinical presentation of CM. Further study is needed to determine the role of vitamin D on prospective hemorrhage risk and whether supplementation may be beneficial.
引用
收藏
页码:216 / 222
页数:7
相关论文
共 19 条
[1]   Symptomatic Cavernous Malformation Presenting with Seizure without Hemorrhage: Analysis of Factors Influencing Clinical Presentation [J].
Agosti, Edoardo ;
Flemming, Kelly D. ;
Lanzino, Giuseppe .
WORLD NEUROSURGERY, 2019, 129 :E387-E392
[2]  
American Geriatrics Society work group on vitamin D supplementation for older adults, 2014, J Am Geriatr Soc, V62, P147, DOI DOI 10.1111/JGS.12631
[3]  
[Anonymous], ROLE VITAMIN D ENDOT
[4]   Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease A Review [J].
Chohan, Muhammad O. ;
Marchio, Serena ;
Morrison, Leslie A. ;
Sidman, Richard L. ;
Cavenee, Webster K. ;
Dejana, Elisabetta ;
Yonas, Howard ;
Pasqualini, Renata ;
Arap, Wadih .
JAMA NEUROLOGY, 2019, 76 (04) :492-500
[5]   Polymorphisms in Inflammatory and Immune Response Genes Associated with Cerebral Cavernous Malformation Type 1 Severity [J].
Choquet, Helene ;
Pawlikowska, Ludmila ;
Nelson, Jeffrey ;
McCulloch, Charles E. ;
Akers, Amy ;
Baca, Beth ;
Khan, Yasir ;
Hart, Blaine ;
Morrison, Leslie ;
Kim, Helen .
CEREBROVASCULAR DISEASES, 2014, 38 (06) :440-447
[6]   Predictors of Initial Presentation with Hemorrhage in Patients with Cavernous Malformations [J].
Flemming, Kelly D. ;
Kumar, Shivram ;
Brown, Robert D., Jr. ;
Lanzino, Giuseppe .
WORLD NEUROSURGERY, 2020, 133 :E767-E773
[7]   Seasonal variation in hemorrhage and focal neurologic deficit due to intracerebral cavernous malformations [J].
Flemming, Kelly D. ;
Brown, Robert D. ;
Link, Michael J. .
JOURNAL OF CLINICAL NEUROSCIENCE, 2015, 22 (06) :969-971
[8]   Strategy for Identifying Repurposed Drugs for the Treatment of Cerebral Cavernous Malformation [J].
Gibson, Christopher C. ;
Zhu, Weiquan ;
Davis, Chadwick T. ;
Bowman-Kirigin, Jay A. ;
Chan, Aubrey C. ;
Ling, Jing ;
Walker, Ashley E. ;
Goitre, Luca ;
Delle Monache, Simona ;
Retta, Saverio Francesco ;
Shiu, Yan-Ting E. ;
Grossmann, Allie H. ;
Thomas, Kirk R. ;
Donato, Anthony J. ;
Lesniewski, Lisa A. ;
Whitehead, Kevin J. ;
Li, Dean Y. .
CIRCULATION, 2015, 131 (03) :289-+
[9]   Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease [J].
Girard, Romuald ;
Khanna, Omaditya ;
Shenkar, Robert ;
Zhang, Lingjiao ;
Wu, Meijing ;
Jesselson, Michael ;
Zeineddine, Hussein A. ;
Gangal, Anupriya ;
Fam, Maged D. ;
Gibson, Christopher C. ;
Whitehead, Kevin J. ;
Li, Dean Y. ;
Liao, James K. ;
Shi, Changbin ;
Awad, Issam A. .
BIOMARKERS IN MEDICINE, 2016, 10 (03) :255-264
[10]   Trends in Dietary Supplement Use Among US Adults From 1999-2012 [J].
Kantor, Elizabeth D. ;
Rehm, Colin D. ;
Du, Mengmeng ;
White, Emily ;
Giovannucci, Edward L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (14) :1464-1474